PERK Pathway and Neurodegenerative Disease: To Inhibit or to Activate?

Talya Shacham 1,2,†, Chaitanya Patel 1,2,† and Gerardo Z. Lederkremer 1,2,*

1 Cell Biology Division, George Wise Faculty of Life Sciences, The Shmunis School of Biomedicine and Cancer Research, Tel Aviv University, Tel Aviv 69978, Israel; talyash1@mail.tau.ac.il (T.S.); chaitanyspatel@gmail.com (C.P.)
2 Sagol School of Neuroscience, Tel Aviv University, Tel Aviv 69978, Israel
*
Correspondence: gerardol@tauex.tau.ac.il; Tel.: +972-3-640-9239
† These authors contributed equally to this work.

Abstract: With the extension of life span in recent decades, there is an increasing burden of late-onset neurodegenerative diseases, for which effective treatments are lacking. Neurodegenerative diseases include the widespread Alzheimer’s disease (AD) and Parkinson’s disease (PD), the less frequent Huntington’s disease (HD) and Amyotrophic Lateral Sclerosis (ALS) and also rare early-onset diseases linked to mutations that cause protein aggregation or loss of function in genes that maintain protein homeostasis. The difficulties in applying gene therapy approaches to tackle these diseases is drawing increasing attention to strategies that aim to inhibit cellular toxicity and restore homeostasis by intervening in cellular pathways. These include the unfolded protein response (UPR), activated in response to endoplasmic reticulum (ER) stress, a cellular affliction that is shared by these diseases. Special focus is turned to the PKR-like ER kinase (PERK) pathway of the UPR as a target for intervention. However, the complexity of the pathway and its ability to promote cell survival or death, depending on ER stress resolution, has led to some confusion in conflicting studies. Both inhibition and activation of the PERK pathway have been reported to be beneficial in disease models, although there are also some reports where they are counterproductive. Although with the current knowledge a definitive answer cannot be given on whether it is better to activate or to inhibit the pathway, the most encouraging strategies appear to rely on boosting some steps without compromising downstream recovery.

Keywords: ER stress; unfolded protein response; integrated stress response; eIF2; Alzheimer’s disease; Parkinson’s disease; Huntington’s disease; ALS

1. Introduction

The accumulation of unfolded or misfolded secretory proteins, which causes a serious disturbance in endoplasmic reticulum (ER) function, termed ER stress, is a common feature in neurodegenerative diseases [1–3]. ER stress activates the UPR, which we will detail later on. The unfolded protein response (UPR) initially triggers cell-protective cascades, aimed at reducing the ER load of unfolded proteins, by transiently inhibiting protein synthesis and upregulating the protein folding and degradation machineries. Because the cell insult remains, usually in the form of mutant misfolded aggregation-prone proteins, the ER stress is not resolved, and the prolonged UPR initiates in the long-term pro-apoptotic processes, leading to cell death. Owing to insufficient compensatory mechanisms and scarce regeneration, the consequences in the central nervous system are profound, and are a main cause of neurodegeneration.

Ongoing gene therapy approaches, especially in the case of monogenic diseases such as Huntington’s disease (HD), attempt to reduce or eliminate the pathogenic mutant proteins, using siRNA [4], antisense knockdown [5] or allele-specific CRISPR/Cas9-mediated gene editing [6]. However, there is still a roadblock in attaining efficient delivery. Another
approach centers on blocking the cellular toxicity caused by the misfolded proteins. Reduction of ER stress is an attractive aim, and can be accomplished by several strategies. One involves the targeting of the UPR pathways.

ER stress in neurodegenerative diseases activates all three pathways of the mammalian UPR, which we will detail below. However, it is becoming apparent that the PERK pathway has a main role in the generation and also in the resolution of the ensuing cytotoxicity. The PERK pathway is an increasing target for many studies that try to develop therapeutic approaches for neurodegenerative diseases that have so far remained refractory to any effective treatment. These include major, widespread diseases, such as AD, PD and ALS, as well as more circumscribed diseases such as HD and rare genetic diseases such as vanishing white matter disease (VWMD) and spinocerebellar ataxias. Perplexingly, multiple reports in recent years have successfully applied approaches that either inhibit or activate the PERK pathway in a variety of diseases or conditions. This review will focus on the dichotomies involved, i.e., the advantages and disadvantages in these approaches.

2. The Unfolded Protein Response

Protein misfolding, originated in gene mutations or in prion transmission, viral infection, DNA damage, reactive oxygen species (ROS) and other environmental and physiological factors, is responsible for induction of the cellular stress responses [7,8]. Proper protein folding, processing, localization and degradation are all crucial in maintaining protein homeostasis (proteostasis) within a cell. Disruption of proteostasis results in the activation of the cellular stress responses [9]. Accumulation of misfolded proteins in the ER results in ER stress and induction of the UPR, whereas the accumulation of misfolded proteins in the cytosol induces the Heat Shock Response (HSR) [10]. These stress responses are responsible for reducing the unfolded protein load by either halting protein synthesis, by increasing the expression of molecular chaperones to increase folding capacity or by upregulating the protein degradation machinery. The extent of ER stress and the ability to compensate it results in a selective role of the UPR, either pro-adaptive or pro-apoptotic. In case of failure in bringing the cell to homeostasis by the above methods, the UPR triggers initiation of programmed cell death or apoptosis [11,12].

The mammalian UPR is branched into three pathways, each with its UPR sensor, PERK [13], inositol-requiring transmembrane kinase/endoribonuclease 1 (IRE1) [14] and activating transcription factor 6 (ATF6) [15] (Figure 1). These three transmembrane proteins are in an inactive state when bound with the ER chaperone BiP (GRP78, 78 KDa glucose-regulated protein), under normal cellular conditions. Upon binding of a misfolded protein to BiP or directly to the UPR sensor, PERK, IRE1 and ATF6 are released and, thus, activated by dimerization and autophosphorylation for PERK and IRE1, and intermembrane proteolysis for ATF6 [12,16].
Figure 1. Unfolded protein response (UPR) pathways. Accumulated misfolded proteins in the ER cause ER stress, binding BiP and activating the UPR sensors, PERK, IRE1 and ATF6. Activated PERK initiates in the short-term a pro-survival outcome by inhibiting protein translation (reducing ER protein load), activating ATF4-dependent transcription of pro-survival genes and a Nrf2-dependent redox maintenance pathway. In the long term, if ER stress persists, there is activation of pro-apoptotic genes. Activated IRE1 (exemplified here by the prevalent form IRE1α) also induces pro-survival genes to increase protein folding and ERAD capacity. This is achieved through IRE1-dependent splicing of unspliced XBP1 mRNA (XBP1u) to a spliced form (XBP1s), which encodes an active transcription factor. Regulated IRE1 Dependent Decay (RIDD) degrades mRNAs encoding for secretory proteins, reducing the ER load. In this case, there is also activation of pro-apoptotic genes, if ER stress persists, via Jun-N-terminal kinase (JNK) phosphorylation and activation by a complex of IRE1α with TRAF2 and apoptotic-signaling kinase-1 (ASK1). Activated ATF6 is transported to the Golgi complex for cleavage by site 1 and site 2 proteases (S1P, S2P) resulting in an active form released from the membrane, which traffics to the nucleus, inducing protein folding and ERAD genes.

The activation of PERK results in the phosphorylation of the α subunit of eukaryotic translation initiation factor (eIF2α) rendering P-eIF2α (also referred to as eIF2(α-P)), which
in turn transiently halts the synthesis of most cellular proteins by binding to the eIF2B guanine nucleotide exchange factor [16,17]. The P-eIF2α-eIF2B complex inhibits the binding of eIF2 to the initiator Met-tRNA, therefore reducing the ternary complex (eIF2-GTP-Met-tRNA) and inhibiting protein synthesis [18]. Nevertheless, the synthesis of a limited number of proteins is increased, among them the transcription factor 4 (ATF4), C/EBP Homologous protein (CHOP) and growth arrest and DNA damage-inducible protein 34 kDa (GADD34, also called PPP1R15A). The increase in the translation of ATF4 and others is due to the presence of upstream open reading frames (uORFs) in their 5′ UTR [19]. Depending on the dynamics of PERK pathway activation, it can have a pro-adaptive or pro-apoptotic role. Under a pro-adaptive role, the transient translation inhibition reduces ER load. ATF4 then acts through a negative feedback loop by inducing the expression of several genes, one of them the transcription factor CHOP, which in turn induces, among other genes, GADD34. GADD34 forms a complex with protein phosphatase 1 (PP1) resulting in the dephosphorylation of P-eIF2α, release of eIF2B, and thus, reactivation of cellular protein synthesis [20]. P-eIF2α can also be dephosphorylated by a complex of PP1 with a constitutive regulator, CREP (PPP1R15B) [21]. If during this cycle ER stress is reduced, proteostasis is restored. Under a pro-apoptotic role, when ER stress is not resolved, ATF4 increases the expression of CHOP to a level that results in the initiation of apoptosis. CHOP is phosphorylated by p38 MAPK, which promotes its role in apoptosis [22]. Another protein that was recently reported to follow the same uORF-dependent translation is QRICH1, the increased translation of which promotes apoptosis [23].

The ER stress branch of the UPR is part of the conserved intracellular signaling network called the Integrated Stress Response (ISR) [16]. The ISR is induced by proteostasis defects, nutrient deprivation, viral infection and oxidative stress within the cell. The ISR acts through four eIF2α kinases, activated by different cellular stresses: PERK, PKR, HRI and GCN2 [16,24,25].

Other than its involvement in regulating translation, PERK also acts against oxidative stress. The transcription factor NF-E2-related factor 2 (Nrf2) is another substrate which is phosphorylated and activated by PERK. In normal conditions, Nrf2 is kept inactive by binding to an adaptor of Cullin 3-based E3 ubiquitin ligase, Kelch-like ECH-associated protein 1 (KEAP1). This complex is kept in the cytosol, and Nrf2 is targeted for ubiquitin-mediated degradation [26]. Upon Nrf2 phosphorylation, pNrf2 is released from KEAP1 and traffics to the nucleus, where it activates transcription of genes involved in detoxification, anti-oxidation and metabolism [27,28].

IRE1, the sensor of the second UPR branch, is activated by autophosphorylation and oligomerization upon ER stress. There are two IRE1 variants, IRE1α and IRE1β. IRE1α is the best-studied form, IRE1β being tissue-specific, expressed mostly in the digestive tract [29]. IRE1 activation enables its special endoribonuclease activity, responsible for splicing the mRNA that encodes transcription factor XBP1 [16,30]. XBP1s (spliced form) codes for a active transcription factor, which upregulates genes involved in protein folding and ERAD (e.g., HRD1) [31–33]. In the long term, the RNase activity of IRE1α becomes less specific and can degrade many mRNAs localized to the ER through a process termed Regulated IRE1 Dependent Decay (RIDD). RIDD can also reduce the stability of miRNAs and rRNAs [34,35]. Prolonged stress results in the activation of ASK1 and JNK by pIRE1α, promoting apoptosis.

The third UPR sensor, ATF6, is translocated to the Golgi compartment upon ER stress, where it is cleaved to an active transcription factor by the enzymes site 1 protease (SIP) and site 2 protease (S2P). The activated ATF6 induces the upregulation of ER chaperones and ERAD genes (e.g., BiP, HRD1, SEL1L, Herp) [31,32,36].

3. ER Stress in Neurodegenerative Diseases

Accumulated misfolded proteins in the ER are directed to the ER-associated degradation pathway (ERAD), which involves retrotranslocation to the cytosol, for ubiquitylation and proteasome-dependent degradation. Remarkably, although in most neurodegenerative
diseases the mutant misfolded proteins are expressed in the cytosol and not in the ER, they indirectly cause ER stress, frequently by inhibiting ERAD [3]. The insufficiency of the UPR in compensating the ER stress leads in the long term to cell death.

Unlike most mammalian cell types, neurons have a very limited regeneration rate. Therefore, depletion of neurons due to cell death results in neurodegeneration, a loss of neuronal function in central nervous system tissues. Some of the best known examples of neurodegenerative diseases are AD, PD, HD, ALS, Prion Disease and tauopathies such as Progressive Supranuclear Palsy (PSP) and Frontotemporal Dementia (FTD) [11].

In AD, which is the most prevalent neurodegenerative disorder, pathogenesis is a result of environmental and genetic factors [37]. Manifestation of AD starts with memory impairment, which is caused by depletion of neurons in the hippocampal formation and para-hippocampal gyrus regions of the brain. The specific cell types most affected in AD pathology are the ones which interconnect the hippocampal formation with the association cortices, basal forebrain, thalamus and hypothalamus [38]. AD has been linked to hyperphosphorylation of the Tau protein (pTau), which destabilizes neuronal microtubules causing intracellular neurofibrillary tangles (NFT), and extracellular plaques caused by accumulation of Amyloid-β (Aβ) peptides, due to mutations in the amyloid precursor protein (APP) [37,39,40]. Toxic soluble pTau, Aβ-oligomers and NFT were shown to inhibit ERAD and the proteasome machinery [41,42]. This results in the increase in protein load within the ER, inducing ER stress and activating the UPR [43–45] (Table 1). BiP, pPERK, pIRE1α, P-eIF2α, ATF4 and beta-site APP cleaving enzyme 1 (BACE1) have been found to be upregulated in AD models. Prolonged PERK branch activation in AD was shown to affect memory and promote neurodegeneration by affecting protein synthesis [46,47]. It is still unclear why specific brain regions and cell types are more affected [48]. ER and oxidative stress induced by Aβ/pTau can also lead to activation of the ASK1 branch of the IRE1α pathway [47,49,50]. Under prolonged ER stress, AD brains showed upregulation of pro-apoptotic pathways, especially increased CHOP expression, causing induction of oxidative stress, which further resulted in an increase of Aβ-oligomers and neuronal death [51]. A recent study reported that in the brains of Down Syndrome patients (who have a high propensity to develop AD), there is sustained activation of the PERK pathway, but it fails to regulate anti-oxidant outcomes through Nrf2, therefore exacerbating oxidative stress [52].

| Table 1. UPR pathways in neurodegenerative diseases. |
| Neurodegenerative Disease | UPR Pathway | References |
|--------------------------|-------------|------------|
| AD                       | Upregulation of the PERK pathway | [46,51] |
|                          | Activation of the ASK1 branch of the IRE1α pathway | [47,49,50] |
| PD                       | Increased levels of pPERK and P-eIF2α | [53–55] |
|                          | α-Synuclein aggregates were reported to interact directly with BiP and activate the UPR | [56] |
|                          | α-Synuclein binds RAB1, impairing COPII vesicular trafficking, thus inhibiting ATF6 activation | [57] |
| VWMD                     | Mutations in EIF2B (common branch of PERK pathway and ISR) | [58,59] |
| HD                       | Upregulation of PERK pathway | [60,61] |
|                          | Upregulation of IRE1 and ATF6 pathways | [61,62] |
Table 1. Cont.

| Neurodegenerative Disease | UPR Pathway | References |
|---------------------------|-------------|------------|
| ALS                       | mSOD1 interacts with Derlin1 and activates ASK1 pathway | [63,64] |
|                           | mC9orf72 induces ISR | [65] |
|                           | mFUS induces ISR | [66] |
|                           | mTDP-43 increases ATF6 and XBP-1 activation | [67] |
| Prion disease             | Mutant prion protein activates PERK pathway | [68] |

PD can be caused by mutations in the SNCA gene, which codes for α-synuclein, resulting in the accumulation of mutant α-synuclein in so-called Lewy bodies in the dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc), causing neuronal death [44,53]. The activation of the PERK pathway through increased levels of pPERK and P-eIF2α in patient brains carrying PD and in cellular models has been reported by several studies, suggesting a pro-apoptotic role of the PERK branch in PD [53–55]. Although α-synuclein is not an ER resident protein, it has been reported to interact directly with the machineries involved in vesicular transport, with the ER/Golgi membranes [56] and the outer mitochondrial membrane [69]. α-Synuclein has been shown to activate the UPR through several mechanisms: (1) Some studies showed that α-synuclein oligomers are responsible for the inhibition of the proteasome machinery, (2) α-synuclein aggregates were reported to interact directly with BiP and activate the UPR in PD, although it is unclear how they are translocated into the ER [56] and (3) α-synuclein interacts with RAB1 [70], impairing COPII vesicular trafficking, and therefore, inhibiting ATF6 activation and blocking this pro-adaptive branch of the UPR, leading to apoptosis [57]. Therefore, a simultaneous targeting of the PERK and ATF6 UPR branches could be a possible therapeutic strategy for treating PD.

In models of the rare neurodegenerative disease VWMD, caused by mutations in eIF2B, there is a pernicious downstream effect on the ISR, leading to demyelination of neurons in the white matter of the CNS [71]. Reduction of activity in mutant eIF2α has a similar effect as sustained eIF2α phosphorylation, inhibiting protein synthesis and causing activation of the ATF4 pro-apoptotic outcomes [58,59].

HD is a neurodegenerative disorder caused by the aggregation of mutant huntingtin (mHtt), resulting in a selective neuronal death, starting in the striatum but also extending to the cortex and some other areas of the brain [72–74]. mHtt was shown to cause ER stress and upregulation of UPR markers such as pPERK, P-eIF2α, CHOP, GADD34, BiP, ATF6 and XBP1s in HD models [75,76]. ER stress was observed in HD cellular models [60,61,77–79], in HD animal models [77,80–82], and in postmortem samples from HD patients [77], reviewed in [75,76,83,84]. As mHtt is present in the cytosol and nucleus and not in the ER, the question arises of how it causes ER stress. mHtt was shown to sequester and deplete the cytosolic chaperone p97/VCP and its cofactors Npl4 and Ufd1, which are essential for ERAD. ERAD inhibition leads in turn to protein accumulation in the ER and ER stress [61,78,85]. A similar mechanism of p97 sequestration was observed in a model of polyQ expanded Spinocerebellar ataxia type-3 (SCA3) disease [86]. In the case of HD, soluble mHtt oligomers were found to be the causative agent of ER stress [61] and the main UPR pathway induced was the PERK pathway [60]. As in other neurodegenerative diseases, it is still unclear why specific cell types are more vulnerable, but a very low activity of PERK-mediated eIF2α phosphorylation in striatal neurons was connected to the higher mHtt toxicity in this region [60]. The observed increase in eIF2α phosphorylation in the presence of mHtt was thought to be detrimental, but it was later concluded that it is actually an insufficient cellular attempt to restore homeostasis [87]. Other UPR pathways are also involved; when the IRE1 pathway was compromised, there was compensation by an increase in autophagy, which would help to clear misfolded mHtt [82].
ALS is a fatal neurodegenerative disorder which affects large motor neurons of the brain and spinal cord. Although it is mainly a sporadic disease, about 10% of ALS cases are familial in nature. Familial ALS can be caused by mutation in several genes, including chromosome 9 open reading frame 72 (C9ORF72) [65], TAR DNA binding protein 43 (TDP-43) [67], the RNA binding protein fused in sarcoma (FUS) [66], superoxide dismutase-1 (SOD1) [88] and Ubiquilin-2 (UBQLN2) [44,89,90]. UBQLN2 has a role in targeting misfolded proteins in the cytosol and the nucleus to proteasomal degradation [90]. In addition to ALS, mutations in UBQLN2 have also been associated with FTD. It is involved in the formation of stress granules [91]. Mutant FUS and TDP43 also accumulate in the cytosol in the form of stress granules and induce ER stress [67]. Mutant SOD1 (mSOD1) leads to ALS pathogenicity by causing ER stress and especially by activating the PERK pathway through several mechanisms [92]: (1) mSOD1 interferes with COPII vesicular transport [93], (2) mSOD1 showed interaction with Derlin1, an ER membrane protein involved in ERAD, which impaired the ERAD pathway in ALS models [63,64,94], (3) accumulation of mutant SOD1 was reported in the ER lumen, where it binds BiP, inducing ER-stress. In the latter mechanism, a problem of topology arises, similar to that mentioned above with α-synuclein, as it is unclear how cytosolic SOD1 is translocated into the ER lumen. It was reported that PERK haploinsufficiency has a deleterious effect on mSOD1 model mice [95], but these results were challenged in a recent study, which showed no significant effects in disease progression [96].

Prion diseases, also known as transmissible spongiform encephalopathies (TSEs), are characterized by lesions with spongiform changes, gliosis and neuronal loss [97]. It is caused by the development of a protease resistant form of an abnormally folded cellular prion protein (PrP), leading to its aggregation and induction of ER stress [44,98,99]. All the branches of the UPR were shown upregulated in prion disease models, especially the PERK/eIF2α pathway. In cellular models, upregulation of XBP1s and ATF6 showed protective effect from PrP aggregates. GADD34 overexpression was protective, suggesting that prolonged eIF2α phosphorylation is an important factor in prion pathogenicity [68].

The delicate balance of the cell environment is critical when considering the UPR machinery, and especially the PERK pathway, as therapeutic targets in neurodegenerative diseases. While insufficient activation, as a physiological response to the disease, causes accumulation of unfolded proteins, which interfere with ER function, chronic activation in disease inhibits synthesis of new proteins, leading to their depletion, and activates pro-apoptotic pathways. Both conditions may lead to cell loss, with irreversible damage and neurodegeneration in the long term. Therefore, both approaches of activation or inhibition of the PERK pathway have been considered as potential therapies for a variety of diseases (reviewed in [2,16,30,100–104]).

4. PERK Pathway Activation

Activation of the PERK pathway results in transient protein synthesis inhibition, reducing ER protein load, and inducing cell protective pathways through ATF4 and Nrf2. Chronic reduced PERK activity is detrimental, as seen from PERK mutations in Wolcott-Rallison syndrome, which causes early-onset diabetes, epiphyseal dysplasias and neurodegeneration [105–107]. Additionally, in several tauopathies, PERK variants with reduced activity are a genetic risk factor with high vulnerability to ER stress in cells expressing them [108]. Therefore, targeted PERK pathway activation has been considered as a possible therapeutic approach.

A first strategy that was tried for specific PERK pathway activation was the inhibition of GADD34. GADD34 deletion or expression of a dysfunctional GADD34 had shown beneficial effects in models of Charcot-Marie Tooth and familial ALS diseases [109,110]. GADD34 inhibition impedes the dephosphorylation of P-eIF2α, prolonging the arrest in protein synthesis. The first inhibitor that was identified was the small molecule salubrinal, which showed protection from ER stress in cellular and animal HD, PD, traumatic brain injury (TBI) and excitotoxic neuronal injury models [53,79,111–114] (Figure 2). Salubrinal...
also targets the constitutive PP1 regulatory subunit CReP [111] (Table 2). Guanabenz, a hypotensive drug acting on the β2 adrenergic receptor, showed enhanced effects [115] and was beneficial in familial ALS [116], VWMD [117] and in PD cellular and animal models, by increasing ATF4 levels, leading to upregulation of parkin [118–120]. GADD34 inhibition has also been tried in non-neurodegenerative diseases. For example, in cancer models, Salubrinal combined with 4E1RCat (a dual inhibitor of eIF4E:4E-BP1 and eIF4E:eIF4G) decreased protein synthesis in melanoma cells and impeded tumor growth in mice [121]. Guanabenz improved insulin resistance by upregulating hepatic LepRb expression (involved in lipogenesis and fatty acid β-oxidation) in models of nonalcoholic fatty liver disease [122]. An analogue of guanabenz, Sephin1, developed to remove the β2 adrenergic activity, also showed protective effects in Charcot-Marie-Tooth disease and in a model of familial ALS [123]. Sephin1 delayed the onset of clinical symptoms in a multiple sclerosis (MS) mouse model by inducing prolonged ISR [124], and extended survival of prion infected mice [125]. However, the target specificity of guanabenz and Sephin1 was later challenged [126]. PromISR-6 is another molecule recently found in an in silico screen of guanabenz analogues. Although its target was not identified, it prolonged eIF2α phosphorylation and protein translation inhibition, reducing mutant Htt aggregates and increasing survival in an HD cellular model, apparently by activating autophagy [127]. Raphin1, a drug developed to specifically target CReP, also showed protective effects in an HD mouse model [128].

Figure 2. PERK pathway and small molecule modulators. UPR induction results in dimerization and autophosphorylation of PERK. pPERK catalyzes phosphorylation of the α subunit of the translation factor eIF2 (eIF2(α-P)), which associates with
the guanine nucleotide exchange factor eIF2B, inhibiting its activity and, thus, causing an arrest in transient protein translation. However, this also leads to activation of the translation of ATF4 and other mRNAs with upstream ORFs. ATF4 induces transcription of pro-survival genes and also in the longer term of CHOP, a transcription factor that induces among others the transcription of GADD34. GADD34 forms a complex with PP1, leading to the dephosphorylation of eIF2α-P and resumption of protein synthesis. The constitutively expressed CReP also associates with PP1 to maintain a basal level of eIF2α-P dephosphorylation activity. Activated PERK also phosphorylates Nrf2, causing its release from KEAP1 and allowing its traffic to the nucleus, where pNrf2 induces transcription of redox maintenance genes. In the long term, if ER stress persists, CHOP and QRICH1 accumulation leads to the induction of pro-apoptotic genes. Arrows and modulators in green indicate steps and activators of the PERK pathway, while those in red show steps and compounds that turn off the pathway. Compounds with unknown target mechanism are shown in parentheses.

**Table 2. PERK pathway modulators.**

| Modulators (Compounds) | PERK Pathway Outcome | Neurodegenerative Diseases | Additional Targets |
|------------------------|----------------------|----------------------------|-------------------|
| MK-28                  | Activation (via activating PERK) | HD [87]                   |                   |
| CCT020312              | Activation (Nrf2 branch) | PSP [129]                  |                   |
| GSK260414              | Inhibition (via inhibiting PERK) | Prion Disease [130], PD [131], FD [132], AD [133] | RIPK1 [134] |
| GSK2656157             | Inhibition (via inhibiting PERK) | Traumatic brain injury [135] |                   |
| Echinacoside (ECH)     | Inhibition (activates AKT causing inhibitory phosphorylation of PERK kinase loop) | AD [136,137], PD [138] | Ghrelin receptor [139], Androgen receptor [140] |
| SC79                   | Inhibition (downstream of P-eIF2α, via eIF2B activation) | Prion Disease [141] |                   |
| 2BAct                  | Inhibition (downstream of P-eIF2α, similar activity to that of ISRIB) | VWMD [58] |                   |
| ISRIB                  | Inhibition (downstream of P-eIF2α, similar activity to that of ISRIB) | ALS [142], VWMD [59], AD [143], TBI [144] | Nrf2 [147], AMPK [148] |
| Dibenzyloxylmethane (DBM) | Inhibition (downstream of P-eIF2α, similar activity to that of ISRIB) | FTD [145], Prion disease [145], PD [146] | Nrf2 [147], AMPK [148] |
| Trazodone HCl          | Activation (via inhibiting dephosphorylation of P-eIF2α, inhibits GADD34) | VWMD [117], ALS [116], PD [118,120] | ASICs [151] |
| Guanabenz              | Activation (via inhibiting dephosphorylation of P-eIF2α, inhibits GADD34) | HD [127] | Possibly activator of PERK and other eIF2α kinases [127] |
| PromISR-6 (guanabenz analog, target unknown) | Activation (via inhibiting dephosphorylation of P-eIF2α, inhibits GADD34) | PD [53,56,114], TBI [113], HD [79] | CReP inhibitor, Dusp2 (PAC1) inhibitor [152] |
| Salubrinal             | Activation (via inhibiting dephosphorylation of P-eIF2α, inhibits CReP) | ALS [123], Charcot-Marie-Tooth disease [123], MS [124], Prion Disease [125] | ASICs [151] |
| Sephin1                | Activation (via inhibiting dephosphorylation of P-eIF2α, inhibits CReP) | HD [128] |                   |


Table 2. Cont.

| Modulators (Compounds) | PERK Pathway Outcome | Neurodegenerative Diseases | Additional Targets |
|------------------------|----------------------|---------------------------|-------------------|
| Bruceine D             | Activation           | PD [153]                  | Notch [154], JNK [155] |
| Naringenin (NAR)       | Activation           | PD [156], AD [157,158]    | CRMP-2 [158]      |
| Sulforaphane (SFN)     | Activation           | PD [159–161], HD [162], AD [163–166], MS [167], FRDA [168] | BACE1 [169], NF-κB [170] |
| Tertbutyl-hydroquinene (tBHQ) | Activation | HD [171], AD [172], PD [173] |                  |
| Acetylenic tricyclic bis(cyanoenone) TBE-31 | Activation | FRDA [168] |                  |
| RTA-408 (omaveloxolone) | Activation           | FRDA [174]                |                  |
| Dimethylfumarate (DFM) | Activation           | MS [175], PD [176,177]    | MSK1 and RSK1 [178,179] and others [180] |

The downside of inhibiting P-eIF2α phosphatases is that, as we have seen above, prolonged eIF2α phosphorylation causes extended inhibition of protein synthesis, with the consequent depletion of essential short-lived proteins and extended ATF4 upregulation, leading to expression of downstream pro-apoptotic factors. ATF4 overexpression causes cytotoxicity, as was seen by nigra-striatal degradation in PD animal models [181,182]. Conversely, ATF4- deficient dopaminergic neurons showed attenuated death under a PD neurotoxin and ATF4 inhibition reduced the production of proinflammatory cytokines by mouse microglia in culture [183]. In an MS mouse model, in experimental autoimmune encephalomyelitis, upon deletion of PERK, there was axon degeneration and loss. However, ATF4 inactivation did not show the same result, implying involvement of additional protective factors activated by PERK other than ATF4 [184].

As mentioned above, an additional PERK substrate, besides eIF2α, is Nrf2. Nrf2 activation has beneficial effects in neurodegenerative disease (reviewed in [185]). Several Nrf2 activators have shown protective effects, such as tertbuthyl-hydroquinene, which was shown to be beneficial in cellular models of PD [173], in a rat model of HD [171] and in AβPP/PS1 AD model transgenic mice [172]. Indirect Nrf2 activation was also achieved by sulforaphane (SFN), dimethylfumarate (DFM) and TBE-31. These drugs modify cysteine 151 in KEAP1, resulting in the release of Nrf2 [186]. TBE-31 showed protection by reducing oxidative stress in cellular models of Friedrich Ataxia (FRDA), caused by GAA repeat expansion leading to reduced levels of the mitochondrial protein frataxin [168].

SFN has shown neuroprotection in several disease models of PD [159–161], HD [162], AD [163–166], MS [167] and FRDA [168]. In cancer treatment, it protects against the side effects of chemotherapy by doxorubicin on the heart [187]. DFM is currently used as an oral therapeutic agent for the treatment of relapsing forms of MS [175]. DFM also showed protection in a PD mouse model [176,177]. RTA-408 (omaveloxolone) is currently in clinical trials for the treatment of FRDA [174]. Other drugs that indirectly induce Nrf2 signaling also showed neuroprotective effects; for example, Bruceine D, a drug used in cancer treatment [188,189], which was reported to cause significant improvement in motor function and reduced dopaminergic neuron loss in PD model mice [153]. Another drug that induces Nrf2 signaling, Naringenin, enhanced the neurotrophic effect of astroglia over dopaminergic neurons [156] and improved learning and memory in a rat AD model [157]. However, it was found to have additional targets [158].

Direct activation of PERK can boost the protective phases of the pathway without compromising long-term recovery of eIF2α function by dephosphorylation, as GADD34 is still induced. Direct activators of PERK were identified only recently. The compound CCT020312 was found in a phenotypic screen that assayed for G1/S checkpoint activa-
tors in human colon carcinoma cells [190]. It also inhibited triple-negative breast cancer by G1 phase cell cycle arrest [191]. CCT020312 showed neuroprotection in cellular and mouse models of tauopathies, reducing tau phosphorylation in P301S tau mice and significantly improving their memory and motor function, with a reduction in motoneuron loss [129]. Another compound, MK-28, was recently identified as a potent and selective PERK activator [87] in an evaluation of derivatives of a mother compound, A4, which had been found in an in vitro screen for PERK modulators [192]. MK-28 was the derivative that showed the strongest reduction in ER stress-induced apoptosis in a striatal cell line (STHdhQ111/111) [193] derived from knock-in HD model mice. It also showed much higher efficacy in vitro compared to CCT020312. In vivo MK-28 treatment reduced disease progression, significantly improving motor functions and increasing life expectancy in R6/2 HD model mice [87].

5. PERK Pathway Inhibition

We have described above the benefits of targeted PERK pathway activation using small molecule compounds, as it plays an important role in the ability of the cell to restore homeostasis upon ER stress. However, this is not the case in all studies. Although GADD34 inhibition (leading to PERK pathway activation) has proven beneficial in many studies, involving several neurodegenerative diseases, it was found to be detrimental in other reports. A study in prion-infected tg37 mice showed a negative effect of the GADD34 inhibitor salubrinal, with increased neurotoxicity and reduced survival, and conversely, GADD34 overexpression was protective in cells expressing mutant prion protein (PrPSc) [68]. Similarly, another study reported a detrimental effect of guanabenz in a mouse model of familial ALS, expressing mutant SOD1 [194]. Potential damage may appear in some tissues. For example, GADD34 inhibitors showed toxic effects in pancreatic β cells in both cellular and animal models [195,196].

Under chronical high levels of P-eIF2α, there is lengthy inhibition of protein synthesis, leading to depletion of essential short-lived proteins and extended upregulation of ATF4 with the consequent expression of pro-apoptotic factors. Therefore, an opposite approach of inhibiting the PERK pathway was also tried in several studies (reviewed in [30,102,103,197]). The highly effective PERK inhibitors GSK2606414 and GSK2656157 (Figure 2) were protective in studies of several neurodegenerative diseases. In a P301L tau mouse frontotemporal dementia model, PERK inhibition allowed recovery of protein synthesis and prevented neuronal loss, reducing behavioral symptoms [132]. The PERK inhibitors were also effective in mouse models of prion disease [130], PD [131], TBI [135] and AD [133] and in models of bone cancer and leukemia [198,199]. However, the GSK compounds were reported to also have off-target effects [134]. Another compound, echinacoside, was reported to be a PERK inhibitor as well and showed protection in a PD mouse model [138]. It also extended lifespan in a Caenorhabditis elegans AD model [136] and reduced accumulation of Aβ protein in APPswe, PSEN1dE9 AD model mice expressing APP and PSEN1 mutations [137]. Consistently, conditional PERK knockout improved memory and synaptic plasticity in these AD model mice [51]. However, the outcome of PERK inhibition in AD is complicated by the fact that, similarly to ATF4, the translation of BACE1 is upregulated by phosphorylation of eIF2α. BACE1 proteolytically cleaves the amyloid precursor protein (APP) to produce Aβ. BACE1 levels are increased in AD mouse models and brains of AD patients [200].

Despite the positive influence of PERK inhibition in these studies, there were secondary side effects of pancreatic toxicity, because of the requirement of PERK activity to modulate ER stress which results from the high levels of insulin production in the pancreas [201,202]. A recent approach was to reduce PERK activity but only partially, by an inhibitory phosphorylation of its kinase activation loop. This was done using SC79, an activator of AKT, which is responsible for this phosphorylation [141]. Another approach was the development of compounds that inhibit the pathway downstream of P-eIF2α, partially restoring protein synthesis and inhibiting ATF4 translation. ISRIB was, thus, identified in a
high throughput screen and turned out to bind eIF2B causing it to be resistant to P-eIF2α inhibition [203–206]. ISRIB showed protective effects in a model of prion disease [207], without pancreatic toxicity. ISRIB and an improved derivative, 2BAct, also had beneficial effects on a mouse model of the demyelinating VWMD. ISRIB stabilized and enhanced the remaining activity of mutant eIF2B in this disease [58,59]. ISRIB also increased survival in a cellular ALS model using mutant SOD1-expressing neurons, restoring general protein translation, but still allowing, to a degree, ATF4 translation. In the same study, GSK2606414 did not show the same benefit [142]. In an AD cellular model, ISRIB attenuated Aβ-induced neuronal cell death without affecting Aβ production [143]. Interestingly, ISRIB enhances memory, possibly by restoring protein synthesis, also improving working memory in old mice [208]. Long-term potentiation and cognition were restored and dendritic spines recovered by treatment with ISRIB or GSK2656157 of mice subjected to TBI [135,144]. Two repurposed drugs, trazodone and dibenzoylmethane (DBM), had better pharmacokinetic properties and a similar effect to ISRIB, showing neuroprotection in prion disease and in frontotemporal dementia mouse models and in a marmoset model of PD [145,146]. All these compounds act downstream of P-eIF2α, and therefore, counteract not only the effects of ER stress through PERK, but also the ISR through all four eIF2α kinases.

In the case of PERK pathway inhibition, not all studies showed beneficial effects. In a transgenic rat model of retinal degeneration, rats expressing P23H mutant rhodopsin, which causes ER stress and cell death, treatment with GSK2606414 enhanced photoreceptor apoptosis, even at low doses [209]. In the hAPP-J20 mouse model of AD ISRIB did not improve spatial learning and memory deficits [210].

6. Concluding Remarks

We can conclude that PERK pathway modulation using small molecule drugs is a very promising therapeutic approach for a wide variety of neurodegenerative diseases. It is surprising and puzzling that opposite approaches, both those that inhibit the pathway and those that activate it are reported to be beneficial for many diseases. We have tried to explain in this review the mechanisms that can explain these outcomes. The increase of eIF2α phosphorylation has been seen in virtually all neurodegenerative diseases where it was studied. In some, this could be the cause that activates apoptotic pathways. Therefore, PERK pathway inhibition in these cases can be beneficial. However, in other diseases, increased eIF2α phosphorylation can be a symptom of the cells fighting for their survival. It can actually be an insufficient cellular attempt to restore homeostasis by activating the initial adaptive phases of the PERK pathway. In these cases, PERK activation can be advantageous. Given the complexity of the pathway, different outcomes may result from subtleties in different disease models or in differences in the timing of drug delivery.

Approaches that strongly inhibit the pathway (PERK inhibitors) or that inhibit the turning off of the pathway (GADD34 inhibitors), although showing some initial benefit, can become toxic to many cell types. We believe that the most promising strategies for activation are those that boost the pathway without hindering its deactivation in the long term (PERK activators), and for inhibition, the most promising are those that partially inhibit the downstream effects of P-eIF2α.

As to whether it is best to activate or to inhibit, and for which diseases and conditions, this still remains an open question, pending forthcoming research.

Author Contributions: Conceptualization, G.Z.L.; writing—original draft preparation, all authors; writing—review and editing, all authors. All authors have read and agreed to the published version of the manuscript.

Funding: Research related to this manuscript was funded by the Israel Science Foundation Legacy Heritage Fund (2394/17).

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.
29. Tsuru, A.; Fujimoto, N.; Takahashi, S.; Saito, M.; Nakamura, D.; Iwano, M.; Iwawaki, T.; Kadokura, H.; Ron, D.; Kohno, K. Negative feedback by IRE1β optimizes mucin production in goblet cells. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 2864–2869. [CrossRef]

30. Grandjean, J.M.D.; Madhavan, A.; Cech, L.; Seguinot, B.O.; Paxman, R.J.; Smith, E.; Scampavia, L.; Powers, E.T.; Cooley, C.B.; Plate, L.; et al. Pharmacologic IRE1/XBP1s activation confers targeted ER proteostasis reprogramming. *Nat. Chem. Biol.* **2020**, *16*, 1052–1061. [CrossRef]

31. Kaneko, M.; Yasui, S.; Niinuma, Y.; Arai, K.; Omura, T.; Okuma, Y.; Nomura, Y. A different pathway in the endoplasmic reticulum stress-induced expression of human HRD1 and SEL1 genes. *FEBS Lett.* **2007**, *581*, 5355–5360. [CrossRef]

32. Lee, A.-H.; Ikawa, N.N.; Gilmer, L.H. XBP-1 Regulates a Subset of Endoplasmic Reticulum Resident Chaperone Genes in the Unfolded Protein Response. *Mol. Cell. Biol.* **2003**, *23*, 7448–7459. [CrossRef] [PubMed]

33. Yoshida, H.; Matsui, T.; Yamamoto, A.; Okada, T.; Mori, K. XBP1 mRNA Is Induced by ATF6 and Spliced by IRE1 in Response to ER Stress to Produce a Highly Active Transcription Factor. *Cell* **2001**, *107*, 881–891. [CrossRef]

34. Bashir, S.; Banday, M.; Qadri, O.; Bashir, A.; Hilal, N.; Nida i, F.; Rader, S.; Fazli, K.M. The molecular mechanism and functional diversity of UPR signaling sensor IRE1. *Life Sci.* **2021**, *265*, 118740. [CrossRef] [PubMed]

35. Hollien, J.; Weissman, J.S. Decay of endoplasmic reticulum-localized mRNAs during the unfolded protein response. *Science* **2006**, *313*, 104–107. [CrossRef]

36. Ma, Y.; Hendershot, L.M. Herp is dually regulated by both the endoplasmic reticulum stress-specific branch of the unfolded protein response and a branch that is shared with other cellular stress pathways. *J. Biol. Chem.* **2004**, *279*, 13792–13799. [CrossRef]

37. Guo, T.; Zhang, D.; Zeng, Y.; Huang, T.Y.; Xu, H.; Zhao, Y. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease. *Mol. Neurodegener.* **2020**, *15*. [CrossRef]

38. Hyman, B.T.; Van Hoesen, G.W.; Damasio, A.R.; Barnes, C.L. Alzheimer’s disease: Cell-specific pathology isolates the hippocampal formation. *Science* **1984**, *225*, 1168–1170. [CrossRef]

39. Kinney, J.W.; Bemiller, S.M.; Murtishaw, A.S.; Leisgang, A.M.; Salazar, A.M.; Lamb, B.T. Inflammation as a central mechanism in Alzheimer’s disease. *Alzheimer’s Dement. Transl. Res. Clin. Interv.* **2018**, *4*, 575–590. [CrossRef] [PubMed]

40. Esler, W.P.; Stimson, E.R.; Jennings, J.M.; Vinters, H.V.; Ghilardi, J.R.; Lee, J.P.; Mantyh, P.W.; Maggio, J.E. Alzheimer’s Disease Amyloid Propagation by a Template-Dependent Dock-Lock Mechanism. *Biochemistry* **2000**, *39*, 6288–6295. [CrossRef]

41. Perry, G.; Nunomura, A.; Hirai, K.; Zhu, X.; Prez, M.; Avila, J.; Castellani, R.J.; Atwood, C.S.; Aliev, G.; Sayre, L.M.; et al. Is oxidative damage the fundamental pathogenic mechanism of Alzheimer’s and other neurodegenerative diseases? *Free Radic. Biol. Med.* **2002**, *33*, 1475–1479. [CrossRef]

42. Abisambra, J.F.; Jinwal, U.K.; Blair, L.J.; O’Leary, J.C.; Li, Q.; Brady, S.; Wang, L.; Guidi, C.E.; Zhang, B.; Nordhues, B.A.; et al. Tau Accumulation Activates the Unfolded Protein Response by Impairing Endoplasmic Reticulum-Associated Degradation. *J. Neurosci.*, **2013**, *33*, 9498–9507. [CrossRef] [PubMed]

43. Hoozemans, J.J.M.; Veerhuis, R.; Van Haastert, E.S.; Rozemuller, J.M.; Baas, F.; Eikelenboom, P.; Scheper, W. The unfolded protein response and a branch that is shared with other cellular stress pathways. *J. Biol. Chem.* **2004**, *279*, 13792–13799. [CrossRef]

44. Lindholm, D.; Wootz, H.; Korhonen, L. ER stress and neurodegenerative diseases. *Cell Death Differ.* **2006**, *13*, 385–392. [CrossRef] [PubMed]

45. Montibeller, L.; de Belleruche, J. Amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease (AD) are characterised by differential activation of ER stress pathways: Focus on UPR target genes. *Cell Stress Chaperones* **2018**, *23*, 897–912. [CrossRef]

46. Ohno, M. PERK as a hub of multiple pathogenic pathways leading to memory deficits and neurodegeneration in Alzheimer’s disease. *Brain Res. Bull.* **2018**, *141*, 72–78. [CrossRef]

47. Salminen, A.; Kauppinen, A.; Suuronen, T.; Kaarniranta, K.; Ojala, J. ER stress in Alzheimer’s disease: A novel neuronal trigger for inflammation and Alzheimer’s pathology. *J. Neuroinflamm.* **2009**, *6*, 41. [CrossRef]

48. Muratore, C.; Zhou, C.; Liao, M.; Fernandez, M.A.; Taylor, W.M.; Lagomarsino, V.N.; Pearse, R.V.; Rice, H.C.; Negri, J.M.; He, A.; et al. Cell-type Dependent Alzheimer’s Disease Phenotypes: Probing the Biology of Selective Neuronal Vulnerability. *Stem Cell Rep.* **2017**, *9*, 1868–1884. [CrossRef]

49. Kadowaki, H.; Nishihito, H.; Urano, F.; Sadamitsu, C.; Matsuzawa, A.; Takeda, K.; Masutani, H.; Yodoi, J.; Urano, Y.; Nagano, T.; et al. Amyloid beta induces neuronal cell death through ROS-mediated ASK1 activation. *Cell Death Differ.* **2005**, *12*, 19–24. [CrossRef] [PubMed]

50. Song, J.; Park, K.A.; Lee, W.T.; Lee, J.E. Apoptosis Signal Regulating Kinase 1 (ASK1): Potential as a Therapeutic Target for Alzheimer’s Disease. *Int. J. Mol. Sci.* **2014**, *15*, 2119–2129. [CrossRef]

51. Ma, T.; Trinh, M.A.; Wexler, A.J.; Bourbon, C.; Gatti, E.; Pierre, P.; Cavener, D.R.; Klann, E. Suppression of eIF2α kinases alleviates Alzheimer’s disease-related plasticity and memory deficits. *Nat. Neurosci.* **2013**, *16*, 1299–1305. [CrossRef]

52. Lanzilliotta, C.; Zuliani, I.; Tramutola, A.; Barone, E.; Blarzino, C.; Fogliero, V.; Caforio, M.; Valentini, D.; Villani, A.; Locatelli, F.; et al. Chronic PERK induction promotes Alzheimer-like neuropathology in Down syndrome: Insights for therapeutic intervention. *Prog. Neurobiol.* **2021**, *196*, 101892. [CrossRef] [PubMed]

53. Colla, E.; Coune, P.; Liu, Y.; Pletnikova, O.; Troncoso, J.C.; Iwatsubo, T.; Schneider, B.L.; Lee, M.K. Endoplasmic reticulum stress is important for the manifestations of α-synucleinopathy in vivo. *J. Neurosci.* **2012**, *32*, 3306–3320. [CrossRef]

54. Hoozemans, J.J.; van Haastert, E.S.; Eikelenboom, P.; de Vos, R.A.; Rozemuller, J.M.; Scheper, W. Activation of the unfolded protein response in Parkinson’s disease. *Biochem. Biophys. Res. Commun.* **2007**, *354*, 707–711. [CrossRef]
55. Ryu, E.J.; Harding, H.P.; Angelastro, J.M.; Vitolo, O.V.; Ron, D.; Greene, L.A. Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson’s disease. *J. Neurosci.* 2002, 22, 10690–10698. [CrossRef]

56. Colla, E.; Jensen, P.H.; Pletnikova, O.; Troncoso, J.C.; Glabe, C.; Lee, M.K. Accumulation of toxic alpha-synuclein oligomer within endoplasmic reticulum occurs in alpha-synucleinopathy in vivo. *J. Neurosci.* 2012, 32, 3301–3305. [CrossRef]

57. Creedle, J.J.; Forcelli, P.A.; Delannoy, M.; Oaks, A.W.; Permaul, E.; Berry, D.L.; Duka, V.; Wills, J.; Sidhu, A. α-Synuclein-mediated inhibition of ATF6 processing into COPII vesicles disrupts UPR signaling in Parkinson’s disease. *Neurobiol. Dis.* 2015, 76, 112–125. [CrossRef]

58. Wong, Y.L.; LeBon, L.; Edalji, R.; Lim, H.B.; Sun, C.; Sidrauski, C. The small molecule ISRIB rescues the stability and activity of Vanishing White Matter Disease eIF2β mutant complexes. *eLife* 2018, 7, e32733. [CrossRef]

59. Wong, Y.L.; LeBon, L.; Basso, A.M.; Kohlihaas, K.L.; Nikkel, A.L.; Robb, H.M.; Donnelly-Roberts, D.L.; Prakash, J.; Swensen, A.M.; Rubinstein, N.D.; et al. eIF2β activator prevents neurological defects caused by a chronic integrated stress response. *eLife* 2019, 8, e42940. [CrossRef] [PubMed]

60. Leitman, J.; Barak, B.; Benyair, R.; Shenkman, M.; Ashery, U.; Hartl, F.U.; Lederkremer, G.Z. ER stress-induced eIF2α phosphorylation underlies sensitivity of striatal neurons to pathogenic huntingtin. *PLoS ONE* 2014, 9, e90803. [CrossRef] [PubMed]

61. Leitman, J.; Ulrich Hartl, F.; Lederkremer, G.Z. Soluble forms of polyQ-expanded huntingtin rather than large aggregates cause endoplasmic reticulum stress. *Nat. Commun.* 2013, 4, 2753. [CrossRef] [PubMed]

62. Lee, H.; Noh, J.-Y.; Oh, Y.; Kim, Y.; Chang, J.-W.; Chung, C.-W.; Lee, S.-T.; Kim, M.; Ryu, H.; Jung, Y.-K. IRE1 plays an essential role in ER stress-mediated aggregation of mutant huntingtin via the inhibition of autophagy. *Hum. Mol. Genet.* 2012, 21, 101–114. [CrossRef]

63. Nishitoh, H.; Kadowaki, H.; Nagai, A.; Maruyama, T.; Yokota, T.; Fukutomi, H.; Noguchi, T.; Matsuzawa, A.; Takeda, K.; Ichijo, H. ALS-linked mutant SOD1 induces ER stress- and ASK1-dependent motor neuron death by targeting Derlin-1. *Genes. Dev.* 2008, 22, 1451–1464. [CrossRef]

64. Mori, A.; Yamashita, S.; Uchino, K.; Suga, T.; Ikeda, T.; Takamatsu, K.; Ishizaki, M.; Koide, T.; Kimura, E.; Mita, S.; et al. Derlin-1 overexpression ameliorates mutant SOD1-induced endoplasmic reticulum stress by reducing mutant SOD1 accumulation. *Neurochem. Int.* 2011, 58, 344–353. [CrossRef]

65. Westergard, T.; McAvoy, K.; Russell, K.; Wen, X.; Pang, Y.; Morris, B.; Pasinelli, P.; Trotti, D.; Haessler, A. Repeat-associated non-AUG translation in C9orf72-ALS/FTD is driven by neuronal excitation and stress. *EMBO Mol. Med.* 2019, 11. [CrossRef]

66. López-Erauskin, J.; Tadokoro, T.; Baughn, M.W.; Myers, B.; McAlonis-Downes, M.; Chillon-Marinus, C.; Asiaban, J.N.; Artates, J.; Bui, A.T.; Vetto, A.P.; et al. ALS/FTD-Linked Mutation in FUS Suppresses Intra-axonal Protein Synthesis and Drives Disease Without Nuclear Loss-of-Function of FUS. *Neuron* 2018, 100, 816–830.e817. [CrossRef] [PubMed]

67. Walker, A.K.; Soo, K.Y.; Sundaramoorthy, V.; Parakh, S.; Ma, Y.; Farg, M.A.; Wallace, R.H.; Crouch, P.J.; Turner, B.J.; Horne, M.K.; et al. ALS-Associated TDP-43 Induces Endoplasmic Reticulum Stress, Which Drives Cytoplasmic TDP-43 Accumulation and Stress Granule Formation. *PLoS ONE* 2013, 8, e81170. [CrossRef] [PubMed]

68. Moreno, J.A.; Radford, H.; Peretti, D.; Steinert, J.R.; Verity, N.; Martin, M.G.; Halliday, M.; Morgan, J.; Dinsdale, D.; Ortori, C.A.; et al. Sustained translational repression by eIF2α-P mediates prion neurodegeneration. *Nature* 2012, 485, 507–511. [CrossRef] [PubMed]

69. Colla, E.; Miraglia, F.; Ricci, A.; Rota, L. Subcellular localization of alpha-synuclein aggregates and their interaction with membranes. *Neural Regen. Res.* 2018, 13, 1136. [CrossRef]

70. Cooper, A.A. α-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson’s Models. *Science* 2006, 313, 324–328. [CrossRef] [PubMed]

71. Lin, W. Impaired eIF2β activity in oligodendrocytes contributes to VWMD pathogenesis. *Neural Regen. Res.* 2015, 10, 195–197. [CrossRef]

72. Reiner, A.; Albin, R.L.; Anderson, K.D.; D’Amato, C.J.; Penney, J.B.; Young, A.B. Differential loss of striatal projection neurons in Huntington disease. *Proc. Natl. Acad. Sci. USA* 1988, 85, 5733–5737. [CrossRef] [PubMed]

73. Rosas, H.D.; Koroshetz, W.J.; Chen, Y.I.; Skeuse, C.; Vangel, M.; Cudkowicz, M.E.; Caplan, K.; Marek, K.; Seidman, L.J.; Makris, N.; et al. Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis. *Neurology* 2003, 60, 1615–1620. [CrossRef] [PubMed]

74. Vonsattel, J.P.; Myers, R.H.; Stevens, T.J.; Ferrante, R.J.; Bird, E.D.; Richardson, E.P., Jr. Neuropathological classification of Huntington’s disease. *J. Neuropathol. Exp. Neurol.* 1985, 44, 559–577. [CrossRef]

75. Shacham, T.; Sharma, N.; Lederkremer, G.Z. Protein Misfolding and ER Stress in Huntington’s Disease. *Front. Mol. Biosci.* 2019, 6, 20. [CrossRef]

76. Vidal, R.; Caballero, B.; Couve, A.; Hetz, C. Converging pathways in the occurrence of endoplasmic reticulum (ER) stress in Huntington’s disease. *Curr. Mol. Med.* 2011, 11, 1–12. [CrossRef] [PubMed]

77. Carnemolla, A.; Fossale, E.; Agostoni, E.; Michelazzi, S.; Calligaris, R.; De Maso, L.; Del Sal, G.; MacDonald, M.E.; Persichetti, F. Rsi1 is involved in endoplasmic reticulum stress response in Huntington disease. *J. Biol. Chem.* 2009, 284, 18167–18173. [CrossRef] [PubMed]
Biomolecules 2021, 89. Hjerpe, R.; Bett, J.S.; Keuss, M.J.; Solovyova, A.; McWilliams, T.G.; Johnson, C.; Sahu, I.; Varghese, J.; Wood, N.; Wightman, 100. Gonzalez-Teuber, V.; Albert-Gasco, H.; Auyeung, V.C.; Papa, F.R.; Mallucci, G.R.; Hetz, C. Small Molecules to Improve ER

Brain Res. 99. Mays, C.E.; Soto, C. The stress of prion disease.

J. Neurochem. 98. Chiesa, R. The elusive role of the prion protein and the mechanism of toxicity in prion disease.

J. Biol. Chem. 97. Jeffrey, M.; McGovern, G.; Sisó, S.; González, L. Cellular and sub-cellular pathology of animal prion diseases: Relationship between morphological changes, accumulation of abnormal prion protein and clinical disease.

Proc. Natl. Acad. Sci. USA 96. Dzhashiashvili, Y.; Monckton, C.P.; Shah, H.S.; Kunjamma, R.B.; Popko, B. The UPR-PERK pathway is not a promising therapeutic target for mutant SOD1-induced ALS. Neurobiol. Dis. 2019, 111, 1062–1073. [CrossRef] [PubMed]

Sci. Rep. 95. Wang, L.; Popko, B.; Roos, R.P. The unfolded protein response in familial amyotrophic lateral sclerosis. Human Mol. Genet. 2011, 20, 1008–1015. [CrossRef]

Neurobiol. Mol. 94. Tsuburaya, N.; Homma, K.; Higuchi, T.; Balia, A.; Yamakoshi, H.; Shibata, N.; Nakamura, S.; Nakagawa, H.; Ikeda, S.I.; Umezawa, A. PML-dependent ER-Golgi transport dysfunction is a common pathogenic mechanism in SOD1, TDP-43 and FUS-associated ALS. Acta Neuropathol. 2015, 130, 679–697. [CrossRef]

Hum. Mol. Genet. 93. Soo, K.Y.; Halloran, M.; Sundaramoorthy, V.; Parakh, S.; Toth, R.P.; Southam, K.A.; McLean, C.A.; Lock, P.; King, A.; Farg, M.A.; et al. A novel specific PERK activator reduces toxicity and extends survival in Huntington’s disease models. Sci. Rep. 2020, 10, 6875. [CrossRef] [PubMed]

Cell 92. Kanekura, K.; Suzuki, H.; Aiso, S.; Matsuoka, M. ER Stress and Unfolded Protein Response in Amyotrophic Lateral Sclerosis. Mol. Neurobiol. 2009, 39, 81–89. [CrossRef] [PubMed]

Proc. Natl. Acad. Sci. USA 91. Alexander, E.J.; Ghanbari Niaki, A.; Zhang, T.; Sarkar, J.; Liu, Y.; Nirujogi, R.S.; Pandey, A.; Myong, S.; Wang, J. Ubiquilin 2 modulates ALS/FTD-linked FUS-RNA complex dynamics and stress granule formation. Genes. Dev. 2018, 32, 3308–3319. [CrossRef] [PubMed]

Proc. Natl. Acad. Sci. USA 90. Renaud, L.; Picher-Martel, V.; Codron, P.; Julien, J.P. Key role of UBQLN2 in pathogenesis of amyotrophic lateral sclerosis and frontotemporal dementia. Acta Neuropathol. Commun. 2019, 7, 103. [CrossRef] [PubMed]

Trends Pharmacol. Sci. 89. Gonzalez-Teuber, V.; Albert-Gasco, H.; Auyeung, V.C.; Papa, F.R.; Mallucci, G.R.; Hetz, C. Small Molecules to Improve ER Proteostasis in Disease. Trends Pharmacol. Sci. 2019, 40, 684–695. [CrossRef] [PubMed]

Sci. Rep. 88. Chiesa, R. The elusive role of the prion protein and the mechanism of toxicity in prion disease. PLoS Pathog. 2015, 11, e1004745. [CrossRef] [PubMed]

Brain Res. 87. Mays, C.E.; Soto, C. The stress of prion disease. Brain Res. 2016, 1648, 553–560. [CrossRef]

Sci. Rep. 86. Gonzalez-Teuber, V.; Albert-Gasco, H.; Auyeung, V.C.; Papa, F.R.; Mallucci, G.R.; Hetz, C. Small Molecules to Improve ER Proteostasis in Disease. Trends Pharmacol. Sci. 2019, 40, 684–695. [CrossRef] [PubMed]

Sci. Rep. 85. Tsunoda, A.; Higuchi, T.; Balia, A.; Yamakoshi, H.; Shibata, N.; Nakamura, S.; Nakagawa, H.; Ikeda, S.I.; Umezawa, N.; et al. A small-molecule inhibitor of SOD1-Derlin-1 interaction ameliorates pathology in an ALS mouse model. Acta Neuropathol. 2016, 130, 812–826. [CrossRef] [PubMed]
102. Hughes, D.; Mallucci, G.R. The unfolded protein response in neurodegenerative disorders—Therapeutic modulation of the PERK pathway. *FEBS J.* 2019, 286, 342–355. [CrossRef] [PubMed]

103. Rozpedek-Kaminska, W.; Siwecka, N.; Wawrzynkiewicz, A.; Wojtczak, R.; Pytel, D.; Diehl, J.A.; Majsterek, I. The PERK-Dependent Molecular Mechanisms as a Novel Therapeutic Target for Neurodegenerative Diseases. *Int. J. Mol. Sci.* 2020, 21, 2108. [CrossRef] [PubMed]

104. Urra, H.; Hetz, C. Fine-tuning PERK signaling to control cell fate under stress. *Nat. Struct. Mol. Biol.* 2017, 24, 789–790. [CrossRef]

105. Biason-Lauber, A.; Lang-Muritano, M.; Vaccaro, T.; Schoenle, E.J. Loss of kinase activity in a patient with Wolcott-Rallison syndrome caused by a novel mutation in the EIF2AK3 gene. *Diabetes* 2002, 51, 2301–2305. [CrossRef]

106. Delépine, M.; Nicolino, M.; Barrett, T.; Golamouly, M.; Lathrop, G.M.; Julier, C. EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome. *Nat. Genet.* 2000, 25, 406–409. [CrossRef] [PubMed]

107. Boyce, M.; Bryant, K.F.; Jousse, C.; Long, K.; Harding, H.P.; Scheuner, D.; Kaufman, R.J.; Ma, D.; Coen, D.M.; Ron, D.; et al. A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. *Science* 2005, 307, 935–939. [CrossRef]

108. Sokka, A.L.; Putkonen, N.; Mudo, G.; Pryazhnikov, E.; Reijonen, S.; Khiroug, L.; Belluardo, N.; Lindholm, D.; Korhonen, L. Endoplasmic reticulum stress inhibition protects against excitotoxic neuronal injury in the rat brain. *J. Neurosci.* 2007, 27, 901–908. [CrossRef]

109. Boyce, M.; Bryant, K.F.; Jousse, C.; Long, K.; Harding, H.P.; Scheuner, D.; Kaufman, R.J.; Ma, D.; Coen, D.M.; Ron, D.; et al. A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. *Science* 2005, 307, 935–939. [CrossRef]

110. Wang, L.; Popko, B.; Roos, R.P. An enhanced integrated stress response ameliorates mutant SOD1-induced ALS. *Hum. Mol. Genet.* 2014, 23, 2629–2638. [CrossRef]

111. Wang, L.; Popko, B.; Roos, R.P. An enhanced integrated stress response ameliorates mutant SOD1-induced ALS. *Hum. Mol. Genet.* 2014, 23, 2629–2638. [CrossRef]

112. Sokka, A.L.; Putkonen, N.; Mudo, G.; Pryazhnikov, E.; Reijonen, S.; Khiroug, L.; Belluardo, N.; Lindholm, D.; Korhonen, L. Endoplasmic reticulum stress inhibition protects against excitotoxic neuronal injury in the rat brain. *J. Neurosci.* 2007, 27, 901–908. [CrossRef]

113. Wang, Z.-F.; Gao, C.; Chen, W.; Gao, Y.; Wang, H.-C.; Meng, Y.; Luo, C.-L.; Zhang, M.-Y.; Chen, G.; Chen, X.-P.; et al. Salubrinal in Combination With 4E1RCat Synergistically Protects against ER Stress-Induced SH-SY5Y Cell Death via ATF4-parkin Pathway. *Brain Res.* 2014, 1549, 52–62. [CrossRef] [PubMed]

114. Boyce, M.; Bryant, K.F.; Jousse, C.; Long, K.; Harding, H.P.; Scheuner, D.; Kaufman, R.J.; Ma, D.; Coen, D.M.; Ron, D.; et al. A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. *Science* 2005, 307, 935–939. [CrossRef]

115. Tsaytler, P.; Harding, H.P.; Ron, D.; Bertolotti, A. Selective inhibition of a regulatory subunit of protein phosphatase 1 restores proteostasis. *Science* 2011, 332, 91–94. [CrossRef] [PubMed]

116. Wang, L.; Popko, B.; Roos, R.P. Guanabenz acetate attenuates fatty liver and hyperglycemia associated with obesity. *Mol. Neurobiol.* 2020, 57, 2206–2219. [CrossRef] [PubMed]

117. Dooves, S.; Bugiani, M.; Wisse, L.E.; Abbink, T.E.M.; van der Knaap, M.S.; Heine, V.M. Bergmann glia translocation: A new animal model. *Mol. Neurobiol.* 2020, 57, 2206–2219. [CrossRef] [PubMed]

118. Crespillo-Casado, A.; Chambers, J.E.; Fischer, P.M.; Marciniak, S.J.; Ron, D. PPP1R15A-mediated dephosphorylation of eIF2α is unaffected by Sephin1 or Guanabenz. *eLife* 2017, 6. [CrossRef] [PubMed]
127. Sundaram, J.R.; Wu, Y.; Lee, I.C.; George, S.E.; Hota, M.; Ghosh, S.; Kesavapany, S.; Ahmed, M.; Tan, E.K.; Shenolikar, S. PromiSR-6, a Guanabenz Analogue, Improves Cellular Survival in an Experimental Model of Huntington’s Disease. ACS Chem. Neurosci. 2019, 10, 3575–3589. [CrossRef]

128. Krzyzosiak, A.; Sigurdarottir, A.; Luh, L.; Carrara, M.; Das, I.; Schneider, K.; Bertolotti, A. Target-Based Discovery of an Inhibitor of the Regulatory Phosphatase PPP1R15B. Cell 2018, 174, 1216–1228.e1219. [CrossRef]

129. Bruch, J.; Xu, H.; Rösler, T.W.; De Andrade, A.; Kuhn, P.-H.; Lichtenthaler, S.F.; Arzberger, T.; Winklhofer, K.F.; Müller, U.; Höglinger, G.U. PERK activation mitigates tau pathology in vitro and in vivo. EMBO Mol. Med. 2017, 9, 371–384. [CrossRef]

130. Mori, T.; Hayashi, T.; Hayashi, E.; Su, T.P. Sigma-1 receptor chaperone at the ER-mitochondrion interface mediates the mitochondrion-ER-nuclear signaling for cellular survival. PLoS ONE 2013, 8, e76941. [CrossRef]

131. Mercado, G.; Castillo, V.; Soto, P.; López, N.; Axtén, J.M.; Sardi, S.P.; Hoozemans, J.J.M.; Hetz, C. Targeting PERK signaling with the small molecule GSK2606414 prevents neurodegeneration in a model of Parkinson’s disease. Neurobiol. Dis. 2018, 112, 136–148. [CrossRef]

132. Radford, H.; Moreno, J.A.; Verity, N.; Halliday, M.; Mallucci, G.R. PERK inhibition prevents tau-mediated neurodegeneration in a mouse model of frontotemporal dementia. Acta Neuropathol. 2015, 130, 633–642. [CrossRef]

133. Yang, W.; Zhou, X.; Zimmermann, H.R.; Cavener, D.R.; Klann, E.; Ma, T. Repression of the eIF2α kinase PERK alleviates mGluR-LTD impairments in a mouse model of Alzheimer’s disease. Neurobiol. Aging 2016, 41, 19–24. [CrossRef]

134. Rojas-Rivera, D.; Delvaeye, T.; Roelandt, R.; Nerincx, W.; Augustyns, K.; Vandenabeele, P.; Bertrand, M.J.M. When PERK inhibitors turn out to be new potent Ripk1 inhibitors: Critical issues on the specificity and use of GSK2606414 and GSK2656157. Cell Death Differ. 2017, 24, 1100–1110. [CrossRef] [PubMed]

135. Sen, T.; Gupta, R.; Kaiser, H.; Sen, N. Activation of PERK Elicits Memory Impairment through Inactivation of CREB and Downregulation of PSD95 After Traumatic Brain Injury. J. Neurosci. 2017, 37, 5900–5911. [CrossRef] [PubMed]

136. Chen, W.; Lin, H.R.; Wei, C.M.; Luo, X.H.; Sun, M.L.; Yang, Z.Z.; Chen, X.Y.; Wang, H.B. Echinacoside, a phenylethanoid glycoside from Cistanche deserticola, extends lifespan of Caenorhabditis elegans and protects from Abeta-induced toxicity. Biogerontology 2018, 19, 47–65. [CrossRef]

137. Dai, Y.; Han, G.; Xu, S.; Yuan, Y.; Zhao, C.; Ma, T. Echinacoside Suppresses Amyloidogenesis and Modulates F-actin Remodeling by Targeting the ER Stress Sensor PERK in a Mouse Model of Alzheimer’s Disease. Front. Cell Dev. Biol. 2020, 8, 1403. [CrossRef] [PubMed]

138. Zhao, Q.; Gao, J.; Li, W.; Cai, D. Neurotrophic and neurorescue effects of Echinacoside in the subacute MPTP mouse model of Parkinson’s disease. Brain Res. 2010, 1346, 224–236. [CrossRef] [PubMed]

139. Wu, C.J.; Chien, M.Y.; Lin, N.H.; Lin, Y.C.; Chen, W.Y.; Chen, C.H.; Tzen, J.T.C. Echinacoside Isolated from Cistanche tubulosa inhibits benzo(a)pyrene induced DNA adducts in lungs. Mol. Carcinog. 2009, 47–65. [CrossRef]

140. Wu, C.J.; Chien, M.Y.; Lin, N.H.; Lin, Y.C.; Chen, W.Y.; Chen, C.H.; Tzen, J.T.C. Echinacoside Isolated from Cistanche tubulosa, 47–65. [CrossRef]

141. Halliday, M.; Radford, H.; Zents, K.A.M.; Molloy, C.; Moreno, J.A.; Verity, N.C.; Smith, E.; Ortori, C.A.; Barrett, D.A.; Bushell, M.; et al. Repurposed drugs targeting eIF2α-P-mediated translational repression prevent neurodegeneration in mice. Brain 2017, 140, 1768–1783. [CrossRef]

142. Bugallo, R.; Marlin, E.; Balanás, A.; Toledo, E.; Ferrero, R.; Vinueza-Gavilanes, R.; Larrea, L.; Arrasate, M.; Aragón, T. Fine tuning of the unfolded protein response by ISRIB improves neuronal survival in a model of amyotrophic lateral sclerosis. Cell Death Disease 2019, 354, 3575–3589. [CrossRef]

143. Halliday, M.; Radford, H.; Zents, K.A.M.; Molloy, C.; Moreno, J.A.; Verity, N.C.; Smith, E.; Ortori, C.A.; Barrett, D.A.; Bushell, M.; et al. Repurposed drugs targeting eIF2α-P-mediated translational repression prevent neurodegeneration in mice. Brain 2017, 140, 1768–1783. [CrossRef]

144. Chou, A.; Krukowskki, K.; Jopson, T.; Zhu, P.J.; Costa-Mattioli, M.; Walter, P.; Rosi, S. Inhibition of the integrated stress response reverses cognitive deficits after traumatic brain injury. Proc. Natl. Acad. Sci. USA 2017, 114, E6420–E6426. [CrossRef]

145. Halliday, M.; Radford, H.; Zents, K.A.M.; Molloy, C.; Moreno, J.A.; Verity, N.C.; Smith, E.; Ortori, C.A.; Barrett, D.A.; Bushell, M.; et al. Repurposed drugs targeting eIF2α-P-mediated translational repression prevent neurodegeneration in mice. Brain 2017, 140, 1768–1783. [CrossRef]

146. Hamadji, A.; Nuara, S.G.; Gourdon, J.C.; Huot, P. Trazadone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson’s disease. J. Neural. Transm. 2018, 125, 1355–1360. [CrossRef] [PubMed]

147. Thimmulappa, R.K.; Rangasamy, T.; Alam, J.; Biswal, S. Dibenzoylmethane activates Nrf2-dependent detoxification pathway and inhibits benzo(a)pyrene induced DNA adducts in lungs. Med. Chem. 2008, 4, 473–481. [CrossRef] [PubMed]

148. Kim, N.; Kim, H.M.; Lee, E.S.; Lee, J.O.; Lee, H.J.; Lee, S.K.; Moon, J.W.; Kim, J.H.; Kim, J.K.; Kim, S.J.; et al. Dibenzoylmethane activates Nrf2-dependent detoxification pathway and inhibits benzo(a)pyrene induced DNA adducts in lungs. Med. Chem. 2008, 4, 473–481. [CrossRef] [PubMed]

149. Kraus, R.L.; Li, Y.; Jovanovska, A.; Renger, J.J. Trazadone inhibits T-type calcium channels. Neuropharmacology 2007, 53, 308–317. [CrossRef] [PubMed]

150. Aton, S.J.; Seibt, J.; Dumoulin, M.C.; Coleman, T.; Shiraiishi, M.; Frank, M.G. The Sedating Antidepressant Trazadone Impairs Sleep-Dependent Cortical Plasticity. PLoS ONE 2009, 4, e6078. [CrossRef]
151. Callejo, G.; Pattison, L.A.; Greenhalgh, J.C.; Chakraborti, S.;Andreopolou, E.; Hockley, J.R.F.; Smith, E.S.J.; Rahman, T. In silico screening of GMQ-like compounds reveals guanabenz and sephnin as new allosteric modulators of acid-sensing ion channel 3. *Biochem. Pharmacol.* 2020, 174, 113834. [CrossRef]

152. Hamamura, K.; Nishimura, A.; Chen, A.; Takigawa, S.; Sudo, A.; Yokota, H. Salubrinal acts as a Dusp2 inhibitor and suppresses inflammation in anti-collagen antibody-induced arthritis. *Cell. Signal.* 2015, 27, 828–835. [CrossRef]

153. Yang, Y.; Kong, F.; Ding, Q.; Cai, Y.; Hao, Y.; Tang, B. Bruceine D elevates Nrf2 activation to restrain Parkinson’s disease in mice through suppressing oxidative stress and inflammatory response. *Biochem. Biophys. Res. Commun.* 2020, 526, 1013–1020. [CrossRef]

154. Cheng, Z.; Yuan, X.; Qu, Y.; Li, X.; Wu, G.; Li, C.; Zu, X.; Yang, N.; Ke, X.; Zhou, J.; et al. Bruceine D inhibits hepatocellular carcinoma growth by targeting β-catenin/jagged1 pathways. *Cancer Lett.* 2017, 403, 195–205. [CrossRef]

155. Tan, B.; Huang, Y.; Lan, L.; Zhang, B.; Ye, L.; Yan, W.; Wang, F.; Lin, N. Bruceine D induces apoptosis in human non-small cell lung cancer cells through regulating JNK pathway. *Biomed. Pharmacother.* 2019, 117, 109089. [CrossRef]

156. Zhang, R.; Miao, Q.W.; Zhu, C.X.; Zhao, Y.; Liu, L.; Yang, J.; An, L. Sulforaphane ameliorates neurobehavioral deficits and protects the brain from amyloid β oligomerization. *Pharmacol. Res.* 2019, 139, 452–459. [CrossRef]

157. Ghofrani, S.; Joghataei, M.-T.; Mohseni, S.; Baluchnejadmojarad, T.; Bagheri, M.; Khamse, S.; Roghani, M. Naringenin improves learning and memory in an Alzheimer’s disease rat model: Insights into the underlying mechanisms. *Eur. J. Pharmacol.* 2015, 764, 195–201. [CrossRef] [PubMed]

158. Lawal, M.; Olotu, F.A.; Soliman, M.E.S. Across the blood-brain barrier: Neurotherapeutic screening and characterization of naringenin as a novel CRMP-2 inhibitor in the treatment of Alzheimer’s disease using bioinformatics and computational tools. *Comput. Biol. Med.* 2018, 98, 168–177. [CrossRef] [PubMed]

159. Deng, C.; Tao, R.; Yu, S.Z.; Jin, H. Inhibition of 6-hydroxydopamine-induced endoplasmic reticulum stress by sulforaphane through the activation of Nrf2 nuclear translocation. *Mol. Med. Rep.* 2012, 6, 215–219. [CrossRef]

160. Jazwa, A.; Rojo, A.I.; Innamorato, N.G.; Hesse, M.; Fernández-Ruiz, J.; Cuadrado, A. Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism. *Antioxid. Redox Signal.* 2011, 14, 2347–2360. [CrossRef] [PubMed]

161. Morroni, F.; Tarozzi, A.; Sita, G.; Bolondi, C.; Zolezzi Moraga, J.M.; Cantelli-Forti, G.; Hrelia, P. Neuroprotective effect of sulforaphane in 6-hydroxydopamine-lesioned mouse model of Parkinson’s disease. *Neurotoxicology* 2013, 36, 63–71. [CrossRef]

162. Liu, Y.; Hettinger, C.L.; Zhang, D.; Rezvani, K.; Wang, X.; Wang, H. Sulforaphane enhances proteasomal and autophagic activities in mice and is a potential therapeutic reagent for Huntington’s disease. *J. Neurochem.* 2014, 129, 539–547. [CrossRef]

163. Hou, T.T.; Yang, H.Y.; Wang, W.; Wu, Q.Q.; Tian, Y.R.; Jia, J.P. Sulforaphane Inhibits the Generation of Amyloid-β Oligomer and Promotes Spatial Learning and Memory in Alzheimer’s Disease (PS1V97L) Transgenic Mice. *J. Alzheimers Dis.* 2018, 62, 1803–1813. [CrossRef]

164. Kim, H.V.; Kim, H.Y.; Ehrlich, H.Y.; Choi, S.Y.; Kim, D.J.; Kim, Y. Amelioration of Alzheimer’s disease by neuroprotective effect of sulforaphane in animal model. *Amyloid* 2013, 20, 7–12. [CrossRef] [PubMed]

165. Wang, W.; Wei, C.; Quan, M.; Li, T.; Jia, J. Sulforaphane Reverses the Amyloid-β Oligomers Induced Depressive-Like Behavior. *J. Alzheimers Dis.* 2020, 78, 127–137. [CrossRef]

166. Zhang, R.; Miao, Q.W.; Zhu, C.X.; Zhao, Y.; Liu, L.; Yang, J.; An, L. Sulforaphane ameliorates neurobehavioral deficits and protects the brain from amyloid β deposits and peroxidation in mice with Alzheimer-like lesions. *Am. J. Alzheimers Dis. Other Demen.* 2015, 30, 183–191. [CrossRef]

167. Li, B.; Cui, W.; Liu, J.; Li, R.; Liu, Q.; Xie, X.-H.; Ge, X.-L.; Zhang, J.; Song, X.-J.; Wang, Y.; et al. Sulforaphane ameliorates the development of experimental autoimmune encephalomyelitis by antagonizing oxidative stress and Th17-related inflammation in mice. *Exp. Neurol.* 2013, 250, 239–249. [CrossRef] [PubMed]

168. Abeti, R.; Uzen, E.; Renganathan, I.; Honda, T.; Pook, M.A.; Giunti, P. Targeting lipid peroxidation and mitochondrial imbalance in Friedreich’s ataxia. *Pharmacol. Res.* 2015, 99, 344–350. [CrossRef] [PubMed]

169. Youn, K.; Yoon, J.H.; Lee, N.; Lim, G.; Lee, J.; Sang, S.; Ho, C.T.; Jun, M. Discovery of Sulforaphane as a Potent BACE1 Inhibitor Based on Kinetics and Computational Studies. *Nutrients* 2020, 12, 3026. [CrossRef]

170. Heiss, E.; Herhaus, C.; Klimo, K.; Bartsch, H.; Gerhäuser, C. Nuclear factor kappa B is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms. *J. Biol. Chem.* 2001, 276, 32008–32015. [CrossRef]

171. Silva-Palacios, A.; Ostolaza-Chavarría, M.; Bueln-Chontal, M.; Garibay, C.; Hernández-Reséndiz, S.; Roldán, F.J.; Flores, P.L.; Luna-López, A.; Königsb erg, M.; Zazueta, C. 3-NP-induced Huntington’s-like disease impairs Nrf2 activation without loss of cardiac function in aged rats. *Exp. Gerontol.* 2017, 96, 89–98. [CrossRef] [PubMed]

172. Akhter, H.; Katre, A.; Li, L.; Liu, X.; Liu, R.-M. Therapeutic Potential and Anti-Amyloidosis Mechanisms of Tert-Butylhydroquinone for Alzheimer’s Disease. *J. Alzheimers Dis.* 2011, 26, 767–778. [CrossRef] [PubMed]

173. Alarcón-Aguilar, A.; Luna-López, A.; Ventura-Gallegos, J.L.; Lazzarini, R.; Galván-Arzate, S.; González-Puertos, V.Y.; Morán, J.; Santamaría, A.; Königsb erg, M. Primary cultured astrocytes from old rats are capable to activate the Nrf2 response against MPP+ toxicity after bHq pretreatment. *Neurobiol. Aging* 2014, 35, 1901–1912. [CrossRef] [PubMed]

174. Abeti, R.; Baccaro, A.; Esteras, N.; Giunti, P. Novel Nrf2-Inducer Prevents Mitochondrial Defects and Oxidative Stress in Friedreich’s Ataxia Models. *Front. Cell. Neurosci.* 2018, 12, 188. [CrossRef] [PubMed]
175. Linker, R.A.; Lee, D.H.; Ryan, S.; van Dam, A.M.; Conrad, R.; Bista, P.; Zeng, W.; Hronowsky, X.; Buko, A.; Chollate, S.; et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. *Brain* 2011, 134, 678–692. [CrossRef] [PubMed]

176. Campolo, M.; Casili, G.; Biundo, F.; Crupi, R.; Cordaro, M.; Cuzzocrea, S.; Esposito, E. The Neuroprotective Effect of Dimethyl Fumarate in an MPTP-Mouse Model of Parkinson’s Disease: Involvement of Reactive Oxygen Species/Nuclear Factor-xB/Nuclear Transcription Factor Related to NF-2E. *Antioxid. Redox Signal.* 2017, 27, 453–471. [CrossRef]

177. Jing, X.; Shi, H.; Zhang, C.; Ren, M.; Han, M.; Wei, X.; Zhang, X.; Lou, H. Dimethyl fumarate attenuates 6-OHDA-induced neurotoxicity in SH-SY5Y cells and in animal model of Parkinson’s disease by enhancing Nrf2 activity. *Neuroscience* 2015, 286, 131–140. [CrossRef]

178. Andersen, J.L.; Gesser, B.; Funder, E.D.; Nielsen, C.J.F.; Gottfred-Rasmussen, H.; Rasmussen, M.K.; Toth, R.; Gothelf, K.V.; Arthur, J.S.C.; Iversen, L.; et al. Dimethyl Fumarate Targets MSK1, RSK1, 2 and IKKa/β Kinases and Regulates NF-xB/ 
/p65 Activation in Psoriasis: A Demonstration of the Effect on Peripheral Blood Mononuclear Cells, Drawn from Two Patients with Severe Psoriasis Before and After Treatment with Dimethyl Fumarate. *Psoriasis* 2020, 10, 1–11. [CrossRef] [PubMed]

179. Piroli, G.G.; Manuel, A.M.; Patel, T.; Walla, M.D.; Shi, L.; Lanci, S.A.; Wang, J.; Galloway, A.; Ortsini, P.I.; Smith, D.S.; et al. Identification of Novel Protein Targets of Dimethyl Fumarate Modification in Neurons and Astrocytes Reveals Actions Independent of Nrf2 Stabilization. *Mol. Cell. Proteom.* 2019, 18, 504. [CrossRef]

180. Demmings, M.D.; Tennyson, E.C.; Petroff, G.N.; Tarnowski-Garner, H.E.; Cregan, S.P.; Activating transcription factor-4 promotes neuronal death induced by Parkinson’s disease neurotoxins and a-synuclein aggregates. *Cell Death Differ.* 2020, in press. [CrossRef]

181. Gully, J.C.; Sergeyev, V.G.; Bhootada, Y.; Mendez-Gomez, H.; Meyers, C.A.; Zolotukhin, S.; Gorbatyuk, M.S.; Gorbatyuk, O.S. Up-regulation of activating transcription factor 3 induces severe loss of dopamine nigral neurons in a rat model of Parkinson’s disease. *Neurosci. Lett.* 2016, 627, 36–41. [CrossRef]

182. Inoue, T.; Yamakage, H.; Tanaka, M.; Kusakabe, T.; Shimatsu, A.; Satoh-Asahara, N. Oxytocin Suppresses Inflammatory Responses Induced by Lipopolysaccharide through Inhibition of the eIF-2α-ATF4 Pathway in Mouse Microglia. *Cells* 2019, 8, 527. [CrossRef] [PubMed]

183. Stone, S.; Yue, Y.; Stanojlovic, M.; Wu, S.; Karsenty, G.; Lin, W. Neuron-specific PERK inactivation exacerbates neurodegeneration during experimental autoimmune encephalomyelitis. *JCI Insight* 2019, 4, e124232. [CrossRef] [PubMed]

184. Dinkova-Kostova, A.T.; Kostov, R.V.; Kazantsev, A.G. The role of Nrf2 signaling in counteracting neurodegenerative diseases. *FEBS J.* 2018, 285, 3576–3590. [CrossRef]

185. Kostov, R.V.; Knatko, E.V.; McLaughlin, L.A.; Henderson, C.J.; Zheng, S.; Huang, J.T.; Honda, T.; Dinkova-Kostova, A.T. Pharmacokinetics and pharmacodynamics of orally administered acetylenic tricyclic bis(cyanoenone), a highly potent Nrf2 activator with a reversible covalent mode of action. *Biochem. Biophys. Res. Commun.* 2015, 465, 402–407. [CrossRef]

186. Singh, P.; Sharma, R.; McElhanon, K.; Allen, C.D.; Megyesi, J.K.; Beneš, H.; Singh, S.P. Sulforaphane protects the heart from doxorubicin-induced toxicity. *Free Radic. Biol. Med.* 2015, 86, 90–101. [CrossRef]

187. Fan, J.; Ren, D.; Wang, J.; Liu, X.; Zhang, H.; Wu, M.; Yang, G. Bruceine D induces lung cancer cell apoptosis and autophagy via the ROS/MAPK signaling pathway in vivo and in vivo. *Cell Death Dis.* 2020, 11, 126. [CrossRef]

188. Zhang, J.Y.; Lin, M.T.; Tung, H.Y.; Tang, S.L.; Yi, T.; Zhang, Y.Z.; Tang, Y.N.; Zhao, Z.Z.; Chen, H.B. Bruceine D induces apoptosis in human chronic myeloid leukemia K562 cells via mitochondrial pathway. *Am. J. Cancer Res.* 2016, 6, 819–826. [CrossRef]

189. Stockwell, S.R.; Platt, G.; Barrie, S.E.; Zoumpoulidou, G.; te Poel, R.H.; Aherner, G.W.; Wilson, S.C.; Sheldrake, P.; McDonald, E.; Venet, M.; et al. Mechanism-Based Screen for G1/S Checkpoint Activators Identifies a Selective Activator of EIF2AK3/PERK Signalling. *PloS ONE* 2012, 7, e28568. [CrossRef]

190. Li, X.; Yu, X.; Zhou, D.; Chen, B.; Li, W.; Zheng, X.; Zeng, H.; Long, L.; Zhou, W. CCT020312 Inhibits Triple-Negative Breast Cancer Through PERK Pathway-Mediated G1 Phase Cell Cycle Arrest and Apoptosis. *Front. Pharmacol.* 2020, 11, 737. [CrossRef] [PubMed]

191. Wang, H.; Blais, J.; Ron, D.; Cardozo, T. Structural determinants of PERK inhibitor potency and selectivity. *Chem. Biol. Drug Des.* 2010, 76, 480–495. [CrossRef] [PubMed]

192. Trettel, F.; Rigamonti, D.; Hilditch-Maguire, P.; Wheeler, V.C.; Sharp, A.H.; Persichetti, F.; Cattaneo, E.; MacDonald, M.E. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. *Hum. Mol. Genet.* 2015, 24, 285–288. [CrossRef] [PubMed]

193. Vieira, F.G.; Ping, Q.; Moreno, A.J.; Kidd, J.D.; Thompson, K.; Jiang, B.; Lincecum, J.M.; Wang, M.Z.; De Zutter, G.S.; Tassinari, V.R.; et al. Guanabenz Treatment Accelerates Disease in a Mutant SOD1 Mouse Model of ALS. *Antioxid. Redox Signal.* 2011, 678–692. [CrossRef] [PubMed]

194. Trettel, F.; Rigamonti, D.; Hilditch-Maguire, P.; Wheeler, V.C.; Sharp, A.H.; Persichetti, F.; Cattaneo, E.; MacDonald, M.E. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. *Hum. Mol. Genet.* 2015, 24, 285–288. [CrossRef] [PubMed]

195. Singh, P.; Sharma, R.; McElhanon, K.; Allen, C.D.; Megyesi, J.K.; Beneš, H.; Singh, S.P. Sulforaphane protects the heart from doxorubicin-induced toxicity. *Free Radic. Biol. Med.* 2015, 86, 90–101. [CrossRef]

196. Fan, J.; Ren, D.; Wang, J.; Liu, X.; Zhang, H.; Wu, M.; Yang, G. Bruceine D induces lung cancer cell apoptosis and autophagy via the ROS/MAPK signaling pathway in vivo and in vivo. *Cell Death Dis.* 2020, 11, 126. [CrossRef]

197. Zhang, J.Y.; Lin, M.T.; Tung, H.Y.; Tang, S.L.; Yi, T.; Zhang, Y.Z.; Tang, Y.N.; Zhao, Z.Z.; Chen, H.B. Bruceine D induces apoptosis in human chronic myeloid leukemia K562 cells via mitochondrial pathway. *Am. J. Cancer Res.* 2016, 6, 819–826. [CrossRef]

198. Stockwell, S.R.; Platt, G.; Barrie, S.E.; Zoumpoulidou, G.; te Poel, R.H.; Aherner, G.W.; Wilson, S.C.; Sheldrake, P.; McDonald, E.; Venet, M.; et al. Mechanism-Based Screen for G1/S Checkpoint Activators Identifies a Selective Activator of EIF2AK3/PERK Signalling. *PloS ONE* 2012, 7, e28568. [CrossRef]

199. Li, X.; Yu, X.; Zhou, D.; Chen, B.; Li, W.; Zheng, X.; Zeng, H.; Long, L.; Zhou, W. CCT020312 Inhibits Triple-Negative Breast Cancer Through PERK Pathway-Mediated G1 Phase Cell Cycle Arrest and Apoptosis. *Front. Pharmacol.* 2020, 11, 737. [CrossRef] [PubMed]

200. Wang, H.; Blais, J.; Ron, D.; Cardozo, T. Structural determinants of PERK inhibitor potency and selectivity. *Chem. Biol. Drug Des.* 2010, 76, 480–495. [CrossRef] [PubMed]

201. Trettel, F.; Rigamonti, D.; Hilditch-Maguire, P.; Wheeler, V.C.; Sharp, A.H.; Persichetti, F.; Cattaneo, E.; MacDonald, M.E. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. *Hum. Mol. Genet.* 2000, 9, 2799–2809. [CrossRef] [PubMed]

202. Vieira, F.G.; Ping, Q.; Moreno, A.J.; Kidd, J.D.; Thompson, K.; Jiang, B.; Lincecum, J.M.; Wang, M.Z.; De Zutter, G.S.; Tassinari, V.R.; et al. Guanabenz Treatment Accelerates Disease in a Mutant SOD1 Mouse Model of ALS. *Antioxid. Redox Signal.* 2011, 678–692. [CrossRef] [PubMed]
197. González-Quiroz, M.; Blondel, A.; Sagredo, A.; Hetz, C.; Chevet, E.; Pedeux, R. When Endoplasmic Reticulum Proteostasis Meets the DNA Damage Response. *Trends Cell Biol.* 2020, 30, 881–891. [CrossRef] [PubMed]

198. Mao, Y.; Wang, C.; Tian, X.; Huang, Y.; Zhang, Y.; Wu, H.; Yang, S.; Xu, K.; Liu, Y.; Zhang, W.; et al. Endoplasmic Reticulum Stress Contributes to Nociception via Neuroinflammation in a Murine Bone Cancer Pain Model. *Anesthesiology* 2020, 132, 357–372. [CrossRef] [PubMed]

199. Zhang, X.H.; Wang, X.Y.; Zhou, Z.W.; Bai, H.; Shi, L.; Yang, Y.X.; Zhou, S.F.; Zhang, X.C. The combination of digoxin and GSK2606414 exerts synergistic anticancer activity against leukemia in vitro and in vivo. *Biofactors* 2017, 43, 812–820. [CrossRef]

200. O’Connor, T.; Sadleir, K.R.; Maus, E.; Velliquette, R.A.; Zhao, J.; Cole, S.L.; Eimer, W.A.; Hitt, B.; Bembrinster, L.A.; Lammich, S.; et al. Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes amyloidogenesis. *Neuron* 2008, 60, 988–1009. [CrossRef] [PubMed]

201. Atkins, C.; Liu, Q.; Minthorn, E.; Zhang, S.Y.; Figueroa, D.J.; Moss, K.; Stanley, T.B.; Sanders, B.; Goetz, A.; Gaul, N.; et al. Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity. *Cancer Res.* 2013, 73, 1993–2002. [CrossRef]

202. Harding, H.P.; Zyryanova, A.F.; Ron, D. Uncoupling proteostasis and development in vitro with a small molecule inhibitor of the pancreatic endoplasmic reticulum kinase, PERK. *Trends Cell Biol.* 2012, 287, 44338–44344. [CrossRef]

203. Sidrauski, C.; Acosta-Alvear, D.; Khoutorsky, A.; Vedantham, P.; Hearn, B.R.; Li, H.; Gamache, K.; Gallagher, C.M.; Ang, K.K.; Wilson, C.; et al. Pharmacological brake-release of mRNA translation enhances cognitive memory. *eLife* 2013, 2, e00498. [CrossRef]

204. Tsai, J.C.; Miller-Vedam, L.E.; Anand, A.A.; Jaishankar, P.; Nguyen, H.C.; Renslo, A.R.; Frost, A.; Walter, P. Structure of the nucleotide exchange factor eIF2B reveals mechanism of memory-enhancing molecule. *Science* 2018, 359, 339. [CrossRef]

205. Zyryanova, A.F.; Kashiwagi, K.; Rato, C.; Harding, H.P.; Crespillo-Casado, A.; Perera, L.A.; Sakamoto, A.; Nishimoto, M.; Yonemochi, M.; Shirouzu, M.; et al. ISRIB Blunts the Integrated Stress Response by Allosterically Antagonising the Inhibitory Effect of Phosphorylated eIF2 on eIF2B. *Mol. Cell* 2021, 81, 88–103.e106. [CrossRef] [PubMed]

206. Zyryanova, A.F.; Weis, F.; Faille, A.; Alard, A.A.; Crespillo-Casado, A.; Sekine, Y.; Harding, H.P.; Allen, F.; Parts, L.; Fromont, C.; et al. Binding of ISRIB reveals a regulatory site in the nucleotide exchange factor eIF2B. *Science* 2018, 359, 1533–1536. [CrossRef]

207. Halliday, M.; Radford, H.; Sekine, Y.; Moreno, J.; Verity, N.; le Quesne, J.; Ortori, C.A.; Barrett, D.A.; Fromont, C.; Fischer, P.M.; et al. Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity. *Cell Death Dis.* 2015, 6, e1672. [CrossRef] [PubMed]

208. Krukowski, K.; Nolan, A.; Frias, E.S.; Boone, M.; Ureta, G.; Grue, K.; Paladinini, M.S.; Elizarraras, E.; Delgado, L.; Bernales, S.; et al. Small molecule cognitive enhancer reverses age-related memory decline in mice. *eLife* 2020, 9, e62048. [CrossRef]

209. Athanasiou, D.; Aguila, M.; Bellingham, J.; Kanuga, N.; Adamson, P.; Cheethamc, M.E. The role of the ER stress-response protein PERK in rhodopsin retinitis pigmentosa. *Hum. Mol. Genet.* 2017, 26, 4896–4905. [CrossRef] [PubMed]

210. Johnson, E.C.; Kang, J. A small molecule targeting protein translation does not rescue spatial learning and memory deficits in the hAPP-J20 mouse model of Alzheimer’s disease. *PeerJ* 2016, 4, e2565. [CrossRef]